JP6692358B2 - 転移性結腸直腸癌の抗血管新生療法に関連する予測的及び予後的バイオマーカー - Google Patents

転移性結腸直腸癌の抗血管新生療法に関連する予測的及び予後的バイオマーカー Download PDF

Info

Publication number
JP6692358B2
JP6692358B2 JP2017533704A JP2017533704A JP6692358B2 JP 6692358 B2 JP6692358 B2 JP 6692358B2 JP 2017533704 A JP2017533704 A JP 2017533704A JP 2017533704 A JP2017533704 A JP 2017533704A JP 6692358 B2 JP6692358 B2 JP 6692358B2
Authority
JP
Japan
Prior art keywords
vegf
patients
aflibercept
patient
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017533704A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017530372A (ja
JP2017530372A5 (cg-RX-API-DMAC7.html
Inventor
ニコール・ターシャ・シムズ
ボー・ガオ
イザレル・ロウィ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2017530372A publication Critical patent/JP2017530372A/ja
Publication of JP2017530372A5 publication Critical patent/JP2017530372A5/ja
Application granted granted Critical
Publication of JP6692358B2 publication Critical patent/JP6692358B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2017533704A 2014-09-16 2015-09-10 転移性結腸直腸癌の抗血管新生療法に関連する予測的及び予後的バイオマーカー Active JP6692358B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462051091P 2014-09-16 2014-09-16
US62/051,091 2014-09-16
US201562099630P 2015-01-05 2015-01-05
US62/099,630 2015-01-05
PCT/US2015/049279 WO2016044041A1 (en) 2014-09-16 2015-09-10 Predictive and prognostic biomarkers related to anti-angiogenic therapy of metastatic colorectal cancer

Publications (3)

Publication Number Publication Date
JP2017530372A JP2017530372A (ja) 2017-10-12
JP2017530372A5 JP2017530372A5 (cg-RX-API-DMAC7.html) 2018-10-11
JP6692358B2 true JP6692358B2 (ja) 2020-05-13

Family

ID=54207741

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017533704A Active JP6692358B2 (ja) 2014-09-16 2015-09-10 転移性結腸直腸癌の抗血管新生療法に関連する予測的及び予後的バイオマーカー

Country Status (12)

Country Link
US (2) US10525104B2 (cg-RX-API-DMAC7.html)
EP (1) EP3194974B1 (cg-RX-API-DMAC7.html)
JP (1) JP6692358B2 (cg-RX-API-DMAC7.html)
KR (1) KR102471057B1 (cg-RX-API-DMAC7.html)
CN (1) CN107076749B (cg-RX-API-DMAC7.html)
AU (1) AU2015318207B2 (cg-RX-API-DMAC7.html)
CA (1) CA2960890A1 (cg-RX-API-DMAC7.html)
EA (1) EA036671B1 (cg-RX-API-DMAC7.html)
IL (1) IL250905B (cg-RX-API-DMAC7.html)
MX (1) MX382673B (cg-RX-API-DMAC7.html)
WO (1) WO2016044041A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201701664B (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014158287A2 (en) 2013-03-14 2014-10-02 Otraces Inc. A method for improving disease diagnosis using measured analytes
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
AU2016381964B2 (en) 2015-12-30 2024-02-15 Kodiak Sciences Inc. Antibodies and conjugates thereof
EP3405896A4 (en) 2016-01-22 2019-09-25 Otraces Inc. SYSTEMS AND METHOD FOR IMPROVED DIAGNOSIS OF ILLNESSES
AU2018245602B2 (en) 2017-03-31 2021-07-22 Hirotsu Bio Science Inc. Method for predicting therapeutic effect and/or recurrence monitoring in cancer patients
EA202091786A1 (ru) 2018-01-26 2020-10-20 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния Способы и композиции для лечения ангиогенных расстройств с применением агентов против фрэс
WO2019169341A1 (en) 2018-03-02 2019-09-06 Kodiak Sciences Inc. Il-6 antibodies and fusion constructs and conjugates thereof
WO2020165483A1 (es) * 2019-02-15 2020-08-20 Universidad de Córdoba Método de predicción de respuesta a tratamiento del cáncer con agentes antiangiogénicos
EP3997704A4 (en) * 2019-07-13 2023-07-19 Otraces Inc. IMPROVEMENT OF DIAGNOSIS FOR VARIOUS DISEASES USING ACTIVE PROTEINS OF A TUMOR MICROAREA
CN114786731A (zh) 2019-10-10 2022-07-22 科达制药股份有限公司 治疗眼部病症的方法
US20220390456A1 (en) * 2019-10-17 2022-12-08 Board Of Regents, The University Of Texas System Small extracellular vesicle-associated vegf as a predictor for therapeutic responses
MX2022006241A (es) 2019-11-25 2022-08-22 Univ California Inhibidores de vegf de accion prolongada para la neovascularizacion intraocular.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7396664B2 (en) 1999-06-08 2008-07-08 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
CN101283280A (zh) * 2005-08-18 2008-10-08 Zadec私人有限公司 用于诊断结直肠癌的蛋白质标记和所述标记作为所述癌症类型治疗的药物靶点的用途
EP2464366A2 (en) * 2009-08-14 2012-06-20 Allergan, Inc. Methods of treating cancer using growth factor retargeted endopeptidases
SG10201500479XA (en) * 2010-01-19 2015-03-30 Hoffmann La Roche Tumor Tissue Based Biomarkers For Bevacizumab Combination Therapies
MX2013000676A (es) * 2010-07-19 2013-02-27 Hoffmann La Roche Metodo para identificar pacientes con probabilidad incrementada de responder a una terapia anti-cancer.
JO3283B1 (ar) * 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)

Also Published As

Publication number Publication date
IL250905A0 (en) 2017-04-30
MX382673B (es) 2025-03-13
US20200129589A1 (en) 2020-04-30
AU2015318207A1 (en) 2017-04-06
MX2017003387A (es) 2018-01-30
US10525104B2 (en) 2020-01-07
AU2015318207B2 (en) 2021-11-04
US11439683B2 (en) 2022-09-13
ZA201701664B (en) 2018-05-30
EP3194974B1 (en) 2019-10-23
US20170281725A1 (en) 2017-10-05
JP2017530372A (ja) 2017-10-12
IL250905B (en) 2019-12-31
KR102471057B1 (ko) 2022-11-28
CA2960890A1 (en) 2016-03-24
EP3194974A1 (en) 2017-07-26
CN107076749A (zh) 2017-08-18
KR20170055972A (ko) 2017-05-22
EA036671B1 (ru) 2020-12-07
EA201790549A1 (ru) 2017-07-31
WO2016044041A1 (en) 2016-03-24
CN107076749B (zh) 2020-12-29

Similar Documents

Publication Publication Date Title
JP6692358B2 (ja) 転移性結腸直腸癌の抗血管新生療法に関連する予測的及び予後的バイオマーカー
JP6055764B2 (ja) 乳癌の治療のためのベバシズマブ組合せ療法のための血漿バイオマーカー
AU2011281700B2 (en) Blood plasma biomarkers for bevacizumab combination therapies for treatment of pancreatic cancer
JP6057718B2 (ja) ベバシズマブ併用治療のための腫瘍組織に基づくバイオマーカー
JP6685276B2 (ja) 癌に罹患していることが疑われる患者のアフリベルセプトを用いた処置の結果を予測するための方法
JP2021527082A (ja) 新規な免疫チェックポイント阻害剤
CN108496084A (zh) 通过测量血浆生物标记的水平预测疑似患有癌症的患者使用阿柏西普的治疗的结果的方法
MX2013001523A (es) Neuroprolina como biomarcador para terapias combinadas de bevacizumab.
Shen et al. EphA2, vascular endothelial growth factor, and vascular endothelial growth factor correlate with adverse outcomes and poor survival in patients with glioma
EP3304086B1 (en) Method for predicting responsiveness to a combination therapy with lenvatinib and everolimus

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180830

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180830

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190626

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190709

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191009

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200317

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200414

R150 Certificate of patent or registration of utility model

Ref document number: 6692358

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250